CPHC
Canterbury Park Holding Corporation
CPHC has lower modeled downside risk, despite its lower overall score.
LCID
Lucid Group, Inc.
LCID has a slight edge over CPHC overall, supported by stronger valuation and stronger modeled upside.
CPHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
CPHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CPHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.8x | $0.98 | -94% |
| Fair | 17x | $1.66 | -89% |
| Expensive | 60x | $5.98 | -62% |
| Current | 157x | $15.70 | — |
Historical ranges are pointers, not guarantees.
CPHC's PE is in its expensive range at 157x.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CPHC Forward outlook
There aren't enough analyst estimates for CPHC to show an outlook.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CPHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.10 | +$0.37 |
| Q2 2026 | $0.02 | -33% |
| Q1 2026 | -$0.01 | -106% |
| Q4 2025 | -$0.10 | -124% |
| Q3 2025 | -$0.27 | -129% |
| Q2 2025 | $0.03 | -96% |
| Q1 2025 | $0.16 | -91% |
| Q4 2024 | $0.42 | -80% |
CPHC has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CPHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.1M | +4.2% |
| Q2 2026 | $16.2M | +3.2% |
| Q1 2026 | $13.5M | +2.8% |
| Q4 2025 | $12.4M | +3.9% |
| Q3 2025 | $18.3M | -5% |
| Q2 2025 | $15.7M | -3.3% |
| Q1 2025 | $13.1M | -6.8% |
| Q4 2024 | $12M | -4.4% |
CPHC's revenue grew through 2023 and has held roughly level since: $19M last quarter, up 4.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.9% | +3.2 points |
| Q2 2026 | 1.8% | -1 points |
| Q1 2026 | 7.8% | +2.9 points |
| Q4 2025 | 2.6% | +3.5 points |
| Q3 2025 | 5.7% | -13 points |
| Q2 2025 | 2.8% | -4.2 points |
| Q1 2025 | 4.9% | -7.6 points |
| Q4 2024 | -0.8% | -5.5 points |
CPHC has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CPHC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CPHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.7M | +$3.1M |
| Q2 2026 | $3.6M | +11% |
| Q1 2026 | $2.6M | +3.6% |
| Q4 2025 | -$611.3K | +$6.1M |
| Q3 2025 | -$395.3K | -$395.3K |
| Q2 2025 | $3.2M | +78% |
| Q1 2025 | $2.5M | +$3.1M |
| Q4 2024 | -$6.7M | -$5.7M |
CPHC has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CPHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +54.4K shares |
| 1 year | +2.1% | +107K shares |
| 3 years | +5.2% | +258K shares |
| 5 years | +8.8% | +422K shares |
| Available history | +13% | +601K shares |
CPHC has the edge over LCID on shareholder dilution, with a more favorable share count trend.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CPHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.8x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.0x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
CPHC has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CPHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.0 | Neutral |
| Stochastic | 70.6 | Neutral |
CPHC's weekly RSI is 48 (neutral) and its Stochastic is 71 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CPHC PE vs Consumer Cyclical Sector
| Metric | CPHC | Sector median | Relative |
|---|---|---|---|
| PE | 157x | 18x | 771% above |
| PE % | 92 | 47 | 45 pts above |
CPHC is trading at 157x earnings, a 771% premium to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CPHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.8 | 0.3% below |
| 20 week MA | $15.8 | 0.4% below |
| 50 week MA | $15.7 | 0.3% above |
| 100 week MA | $16.9 | 7% below |
| 200 week MA | $19.5 | 19% below |
CPHC has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CPHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $12.4 | -0.5% |
| 2021 | $12.4 | $17.6 | +42% |
| 2022 | $17.6 | $28.8 | +64% |
| 2023 | $28.8 | $20.4 | -29% |
| 2024 | $20.4 | $21.9 | +7.2% |
| 2025 | $21.9 | $15.3 | -30% |
| 2026 YTD | $15.3 | $15.7 | +2.5% |
CPHC has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.